Scientific Programme
Thursday, February 2, 2023
Opening
Time | Presentation Title | Speaker |
08:30-08:40 |
Entering the Future (Welcome to All Participants)
|
Rudi Dierckx |
08:40-08:50 | Outcomes of Focus 1 in 2018 | Stefano Fanti |
08:50-09:00 | Opening and Objectives | Daniela E. Oprea-Lager |
Thursday, February 2, 2023
Staging of Intermediate and High-Risk Prostate Cancer
Chairpersons: Anders Bjartell, Evis Sala, Stefano Fanti
Time | Presentation Title | Speaker |
09:00-09:25 |
Staging Prostate Cancer: Still a Clinical Unmet Need?
|
Anders Bjartell |
09:30-09:55 |
Staging Prostate Cancer: The Evolving Role of Radiology
|
Evis Sala |
10:00-10:25 |
Staging Prostate Cancer: The Evolving Role of Nuclear Medicine
|
Stefano Fanti
|
11:00-11:15 |
Controversy: Should Molecular Imaging Fully Replace Conventional Imaging?
|
Roman Sosnowski
|
11:15-11:22 |
In Favour
|
Irene A. Burger
|
11:23-11:30 |
Against
|
Evis Sala
|
11:30-11:45 |
What Is the Evidence?
|
Igle J. de Jong
|
11:45-12:00 |
Questions & Answers
|
|
12:00-13:00 |
Consensus on Imaging for Staging Intermediate and High-Risk Prostate Cancer
|
Daniela E. Oprea-Lager, Stefano Fanti |
Thursday, February 2, 2023
Imaging of Biochemical Recurrence in Prostate Cancer
Chairpersons: Jochen Walz, Cristina Nanni, Andrei Iagaru
Time | Presentation Title | Speaker |
14:00-14:25 |
Biochemical Recurrence in Prostate Cancer: Still a Clinical Unmet Need?
|
Jochen Walz
|
14:30-14:55 | Biochemical Recurrence in Prostate Cancer: The Evolving Role of Diagnostic Imaging |
Cristina Nanni
|
15:00-15:25 | Biochemical Recurrence in Prostate Cancer: The Evolving Role of Nuclear Medicine |
Andrei Iagaru
|
16:00-16:22 |
Does Early Detection of Biochemical Recurrence Offer Survival Benefit?
|
Bertrand Tombal
|
16:23-16:45 |
Impact of Changing Clinical Management in Biochemical Recurrence Setting
|
Derya Tilki
|
16:45-17:00 | Questions & Answers | |
17:00-18:00 |
Consensus on Imaging for Biochemical Recurrence of Prostate Cancer
|
Andrei Iagaru, Daniela E. Oprea-Lager |
Friday, February 3, 2023
Imaging of Advanced Prostate Cancer
Chairpersons: Karim Fizazi, Nina Tunariu, Irene A. Burger
Time | Presentation Title | Speaker |
09:00-09:25 |
Advanced Prostate Cancer: Still a Clinical Unmet Need?
|
Karim Fizazi
|
09:30-09:55 |
Advanced Prostate Cancer: The Evolving Role of Radiology
|
Nina Tunariu
|
10:00-10:25 |
Advanced Prostate Cancer: The Evolving Role of Nuclear Medicine
|
Irene A. Burger
|
11:00-11:15 | Controversy: Do We Need Next- Generation Imaging Modalities in Advanced Prostate Cancer? |
Joe O’Sullivan
|
11:15-11:22 | In Favour |
Marnix Lam
|
11:23-11:30 | Against |
Cristina Nanni
|
11:30-11:45 |
What Is the Evidence?
|
Derya Yakar
|
11:45-12:00 | Questions & Answers | |
12:00-13:00 | Consensus on Imaging of Advanced Prostate Cancer |
Joe O’Sullivan,
Daniela E. Oprea-Lager
|
Friday, February 3, 2023
Therapy of Advanced Prostate Cancer
Chairpersons: Silke Gillessen, Ken Herrmann, Oliver Sartor
Time | Presentation Title | Speaker |
14:00-14:25 | Advanced Prostate Cancer: Oncological Therapeutic Options |
Silke Gillessen
|
14:30-14:55 |
Advanced Prostate Cancer: PSMA Theranostics Options
|
Ken Herrmann
|
15:00-15:25 |
Therapy of Advanced Prostate Cancer: Still a Clinical Unmet Need?
|
Oliver Sartor |
16:00-16:15 |
Does PSMA Theranostics Offer (Enough) Survival Benefit in Advanced Prostate Cancer? |
Maria De Santis
|
16:15-16:30 |
PSMA Theranostics – the Urologist’s Perspective
|
Alberto Briganti
|
16:30-16:45 |
PSMA Theranostics – the Medical Oncologist’s Perspective
|
Oliver Sartor |
16:45-17:00 | Questions & Answers | |
17:00-18:00 | Consensus on Therapy of Advanced Prostate Cancer |
Silke Gillessen,
Daniela E. Oprea-Lager
|
Saturday, February 4, 2023
Theranostics in Prostate Cancer – A New Kid on the Block
Chairpersons: Stefano Fanti, Daniela E. Oprea-Lager
Time | Presentation Title | Speaker |
09:00-09:20 |
Development of Radiopharmaceuticals for Theranostics Applications
|
Sandra Heskamp
|
09:20-09:40 |
Alpha, Beta or Tandem Therapy: Good, Better, the Best?
|
Mike Sathekge
|
09:40-10:00 | Current and Future Indications for Theranostics Applications in Prostate Cancer | Marnix Lam |
10:00-10:20 |
Radiation Dosimetry for Theranostic Applications in Prostate Cancer
|
Uta Eberlein |
10:50-11:15 |
Clinical Trials on Theranostics in Prostate Cancer
|
Louise Emmett
|
11:15-11:35 |
Clinical Trials with New Oncologic Agents in Prostate Cancer
|
Karim Fizazi
|
11:35-11:55 |
Combining Theranostics with Radiotherapy: A New Direction?
|
Barbara Alicja Jereczek-Fossa
|
11:55-12:15 |
PET/MRI: A New Approach for Functional and Morphological Imaging?
|
Ken Herrmann
|
12:15-12:30 |
Consensus on ‘Relevant Factors to Build a Consensus’
|
all panellists (Chairpersons: Jolanta Kunikowska, Anders Bjartell) |
12:30-12:50 |
Summary of Results and Debate with all Participants
|
all panellists (Chairpersons: Daniela E. Oprea-Lager, Stefano Fanti) |
12:50-13:00 |
Future Directions & Closing Remarks
|
Daniela E. Oprea-Lager, Rudi Dierckx |